Novo Nordisk is working to accelerate the launch of its weight-loss drug Wegovy in India, concerned about lagging behind Eli ...

For the uninitiated, both Zepbound (tirzepatide) and Wegovy (semaglutide) are weight loss drugs. They target hormones that ...

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...

South Korea's health ministry on Friday said it will ban remote prescribing of weight loss medications, including Wegovy.

Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic ...

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...

"I have been on Wegovy for a year and a half," Griffin said, "and have only lost 13 pounds." Despite doing "everything right," including dieting, exercising, and drinking lots of water, she's had ...

WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Several obesity experts said perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications.

Novo Nordisk’s team in India has been pushing the Danish drugmaker’s global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly ...

Officials at the Danish drugmaker have said Wegovy might be introduced in India in 2026 once regulatory approvals are in hand and there is sufficient supply.